Rank - 69 : Mastek

The dip in revenues was primarily owing to lower income generated from the
BT/NHS engagement where project development revenues fully ramped down in the
JAS Q2 quarter as well as adverse foreign exchange conditions (mainly due to
translation losses in pounds denominated inflows from UK). The UK contribution
subsequently came down from 65% to 52%. Notwithstanding these setbacks, Mastek
focused strongly on its products, particularly in insurancethe partnership with
Capita in UK moved to the next phase with Capita standardizing on Elixir for its
customers. A DQ Top50, Mastek was out this year.